Novartis India: Intimation of the Unaudited Financial Results along with the Limited Review Report for the Quarter and half…

What happened

Novartis India (NOVARTIND) filed a disclosure with the exchanges on 3 November 2026 at 07:04 PM titled "Intimation of the Unaudited Financial Results along with the Limited Review Report for the Quarter and half year ended September 30, 2026".

Company snapshot

Novartis India is a small-cap company, with a market value of about ₹4,253 crore.

The stock last traded at ₹1,722.4, against a 52-week range of ₹672.3–₹2,588.8 (33.5% below the high).

Before this filing the shares had moved −12.6% over the month and +5.9% over three months. Average daily turnover over the last 20 sessions was about ₹8.82 crore.

Promoters held 70.68% at the end of Q2 FY27. Foreign institutions owned 0.15% and domestic institutions 1.39%.

What history shows

BCEIE's records show 1 previous results filing from the company since May 2026.

Market-wide, 10,321 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.

In the news

Recent coverage elsewhere (links open the original publisher):

• Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal — Fierce Pharma, 27 Oct 2026
• Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail — Fierce Biotech, 27 Oct 2026
• Earnings call transcript: Novartis beats Q3 2026 EPS forecast, lifts profit outlook — Investing.com, 27 Oct 2026
• Key facts: Novartis (NOVN) Q3 revenue +4%; net profit down 70% — TradingView, 28 Oct 2026
• Novartis CEO says company must stay 'courageous' to pursue breakthroughs — CNBC, 27 Oct 2026

Source

• Exchange filing (PDF)